Overview
In the last decade, there have been notable advancements in treating advanced endometrial cancer (aEC), marked by the introduction of newer therapies in both first-line (1L) and second-line (2L) settings. Molecular profiling of mismatch repair/microsatellite instability (MMR/MSI) has become indispensable for treatment decision-making. However, a scarcity of real-world evidence persists regarding biomarker testing uptake and recent treatment patterns in the rapidly changing treatment landscape . This study seeks to evaluate the adoption of molecular profiling, treatment trends, and patient outcomes among individuals with aEC.
Why this matters
This study is significant for enhancing our understanding of advanced endometrial cancer (aEC). It focuses on molecular profiling, particularly MMR/MSI testing, which guides treatment decisions. Most patients received the MMR/MSI test recommended to guide treatment decisions, and new treatments were used increasingly in recent years. However, some patient groups may be receiving testing less often, especially among marginalized patient groups.
This suggests potential barriers to accessing tailored treatments. These inequities could hinder the integration of innovative treatments. Despite availability of new therapies, outcomes suggest that major unmet need remains in aEC. Continuous educational efforts are crucial for improving access to and utilization of newer FDA-approved treatments, ultimately enhancing patient care and outcomes in aEC.